Welcome to our dedicated page for Clarivate Plc news (Ticker: CLVT), a resource for investors and traders seeking the latest updates and insights on Clarivate Plc stock.
Clarivate Plc (NYSE: CLVT) is described as a leading global provider of transformative intelligence, with news that reflects its activities across Academia & Government, Intellectual Property and Life Sciences & Healthcare. Company announcements frequently highlight new AI-powered tools, analytical reports and customer adoptions that illustrate how Clarivate combines enriched data, analytics and workflow software.
Recent news includes the launch of the Web of Science Research Assistant, a generative AI-powered tool that helps researchers conduct natural-language searches, perform literature reviews and explore visualizations based on more than 120 years of publication and citation data. Clarivate also reports on studies such as the Pulse of the Library report, which surveys thousands of librarians worldwide about AI adoption, open science and budget pressures, and on the annual Highly Cited Researchers list, which recognizes researchers whose work has had broad influence based on Web of Science data.
In Intellectual Property, Clarivate issues updates on solutions like IPfolio and Derwent Patent Monitor, including customer selections by organizations such as Nissan Motor Co., Ltd. and FUJIFILM Holdings Corporation. These stories emphasize how IP management platforms and AI-enabled patent review tools support more efficient IP operations and collaboration between IP and R&D teams.
Life sciences and healthcare news often centers on Clarivate analyses such as the Drugs to Watch report and Companies to Watch reports, which identify emerging therapies and innovative companies using integrated, AI-enhanced datasets. Visitors to this news page can follow Clarivate’s product launches, research reports, customer case studies and investor-related announcements to understand how the company is applying data and AI across its core markets.
Clarivate Plc (NYSE: CLVT) announced it will release its financial results for Q4 and the full year 2021 on March 10, 2022, prior to market opening. The earnings supplement will be available on its investor website at ir.clarivate.com. A conference call and webcast will be held on the same day at 9:00 AM Eastern Time to discuss the results. Investors can join the live audio broadcast by calling specific numbers for the US, Canada, and international participants. A replay will be accessible until March 23, 2022.
Summary not available.
BioWorld, published by Clarivate Plc (NYSE:CLVT), released an in-depth analysis on long COVID-19, affecting over 100 million globally. The report analyzes 40+ studies assessing the syndrome, developed a consensus definition for standardized research, and tracks 41 drugs in development. Despite the biotech industry's focus on COVID-19 treatments, effective therapeutics for long COVID remain scarce, with only three in late-stage trials. The social impact could be significant as researchers continue to explore disease timelines and symptoms across diverse demographics.
Clarivate Plc (NYSE:CLVT) has opened applications for the Eugene Garfield Award™, recognizing early-career scientists in citation analysis. The award, with a $25,000 unrestricted prize, aims to promote diversity and inclusion by encouraging submissions from emerging nations, especially in Africa and Asia. Established in 2017, it honors Dr. Eugene Garfield's legacy in bibliometrics. Applications are due by July 1, 2022, with the winner announced on September 1, 2022. The award seeks innovative approaches to scientific evaluation using citation data.
On February 7, 2022, Clarivate Plc (NYSE: CLVT; CLVT.PR.A) announced a $1.0 billion share repurchase program approved by its Board of Directors, set to execute through December 31, 2023. This program replaces a previous one from August 2021. Additionally, the Board declared a quarterly dividend of $1.3125 per share on its Series A Mandatory Convertible Preferred Shares, payable on March 1, 2022. Jerre Stead, CEO, emphasized the company's strong cash flow and belief in the current share price as a compelling investment opportunity.
Clarivate Plc (NYSE: CLVT) released a report on February 7, 2022, highlighting key trends shaping the medtech industry for the year. The report emphasizes innovation, healthcare decentralization, and mergers and acquisitions as pivotal factors. It notes that while recovery from COVID-19 has resumed, ongoing pressures from renewed cases may affect procedure volumes. The report also provides insights on past medtech trends and the current vaccination landscape, asserting that stakeholders must adapt to these changes for successful market engagement.
Clarivate plc (NYSE: CLVT) filed amendments to its 2020 Form 10-K and 2021 Form 10-Qs, correcting an error related to equity plan treatment in the CPA Global acquisition. The amendments restate financial results affecting income, tax provisions, net income, and shareholders' equity but do not alter GAAP revenues or key non-GAAP metrics. The revised guidance for 2022 projects revenues of $2.8B-$2.88B, adjusted EBITDA of $1.16B-$1.22B, and an organic growth rate of 6.5%. The company anticipates reporting the 2021 financial results in early March.
Clarivate Plc (NYSE:CLVT) released a report from its Institute for Scientific Information™, proposing a new method for analyzing credit attributed to academic authors via citations. As the number of collaborative research papers grows, existing credit analysis methods can become skewed. The report introduces the 'Collaborative CNCI' (Collab-CNCI) to address this issue. It emphasizes that this innovation aims to improve acknowledgment of research achievements and enhance global research collaboration. The report invites feedback from research users to evaluate Collab-CNCI's benefits compared to existing metrics.
The Patent Trend Report 2022 from Clarivate reveals a strong correlation between patent strategy and innovation, with 75% of organizations stating that patents drive further innovation. Over the past year, 69% of patent portfolios have increased, primarily due to higher budgets and executive engagement. Challenges include a lack of C-suite involvement, with 45% of respondents reporting missed opportunities. Many organizations are considering outsourcing their patent activities more, with 44% planning to increase outsourcing in the next year. The report highlights the potential of technology and AI in enhancing patent strategy.
Clarivate plc (NYSE: CLVT) announced a leadership change with Gordon Samson appointed as Chief Product Officer, effective February 1, 2022. He will focus on enhancing customer solutions across Clarivate’s verticals. Mukhtar Ahmed, the outgoing President of the Science Segment, will assist during the transition until April 1, 2022, and will remain in an advisory position until his departure on October 1, 2022. This change aims to prioritize customer-centric strategies and growth in product innovation, furthering Clarivate's One Clarivate Vision.